Literature DB >> 22729709

AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22729709     DOI： 10.1002/ijc.27685

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  4 in total

1.  Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.

Authors:  Raj Kumar; Minky Son; Rohit Bavi; Yuno Lee; Chanin Park; Venkatesh Arulalapperumal; Guang Ping Cao; Hyong-ha Kim; Jung-keun Suh; Yong-seong Kim; Yong Jung Kwon; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

2.  Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction.

Authors:  Cleverson T Soares; Luciana R V Fachin; Ana P F Trombone; Patricia S Rosa; Cássio C Ghidella; Andrea F F Belone
Journal:  Front Med (Lausanne)       Date:  2018-09-24

3.  Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.

Authors:  Jia Shi; Lixiang Chen; Yi Chen; Yunfei Lu; Xiaorong Chen; Zongguo Yang
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

4.  Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma.

Authors:  Tiangen Wu; Yang Ke; Haoran Tang; Chen Liao; Jinze Li; Lin Wang
Journal:  Mol Ther Oncolytics       Date:  2021-06-12       Impact factor: 7.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.